Chapter 5: Recombinant & Synthetic Vaccines

Recombinant & Synthetic Vaccines begins by establishing the historical importance of vaccines in eradicating diseases like smallpox and significantly reducing polio and diphtheria, while highlighting the economic and safety limitations of traditional live attenuated and killed vaccines, such as the risk of reversion to virulence or toxic side effects from bacterial endotoxins. The text explores the development of subunit vaccines, which enhance safety by using purified protective antigens—such as the Hepatitis B surface antigen produced in yeast or genetically inactivated pertussis toxins—rather than whole pathogens. Because purified subunits are often less immunogenic, the chapter details the essential role of immunology in vaccine design, explaining how innate defense mechanisms, including Toll-like receptors, must be triggered to activate the adaptive immune system. It covers the complex cooperation between Antigen-Presenting Cells (APCs), Major Histocompatibility Complexes (MHC), B cells responsible for antibody production, and T cells (CD4 helper and CD8 cytotoxic) that drive cell-mediated immunity. The narrative discusses various biotechnological innovations to improve efficacy, including conjugate vaccines that link polysaccharides to carrier proteins for infant immunity, the use of live attenuated vectors like vaccinia and Salmonella to deliver foreign antigens, and the creation of synthetic peptide vaccines that target specific epitopes. Furthermore, the chapter addresses the challenges of developing DNA vaccines, which utilize plasmid DNA to induce antigen expression within host cells, and the ongoing struggle to combat complex pathogens with "hit-and-stay" strategies like HIV and the multistage malaria parasite Plasmodium falciparum. Finally, it looks toward the frontier of therapeutic vaccines designed not just for prevention but for treating noninfectious conditions, utilizing immune modulation to combat autoimmune disorders and cancers like melanoma.